Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting Life Science Investing
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute Life Science Investing
PRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark Life Science Investing
BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform Life Science Investing
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT Pharmaceutical Investing
Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial Life Science Investing
Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026 Life Science Investing
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus Life Science Investing
